{"analyses":[{"ciLowerLimit":"0.81","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.61","estimateComment":"computed using a cox proportional hazard model stratified by randomization PDL-1 and HPV status","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.14"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.43","upperLimit":"12.62","value":"9.71"},{"groupId":"OG001","lowerLimit":"9.33","upperLimit":"22.01","value":"12.91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"Overall survival was defined as the time from randomization to the date of death from any cause. Participants were censored at the date they were last known to be alive and at the date of randomization if they were randomized but had no follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab 1 mg/kg Q6W","id":"OG000","title":"Treatment A - Platinum Eligible Subgroup"},{"description":"Participants with histologically confirmed Squamous Cell Carcinoma of the Head and Neck (SCCHN) who are platinum naive or have recurred 6 months or more after completion of previous platinum-based chemotherapy.\n\nTreated with Nivolumab 3 mg/kg Q2W + Ipilimumab-Placebo Q6W","id":"OG001","title":"Treatment B - Platinum Eligible Subgroup"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants - Platinum Eligible Subgroup","reportingStatus":"POSTED","timeFrame":"From randomization to death. Approximately 63 Months","title":"Overall Survival (OS) - Platinum Eligible Subgroup","type":"SECONDARY","unitOfMeasure":"Months"}